ReviewHaematologica2024
Role of minimal residual disease assessment in multiple myeloma.
Review in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Increasing Trends of Minimal Residual Disease Measurement in Trials Focusing on Multiple Myeloma Treatment: A Systematic Analysis of Clinical Research Design From 2014 to 2025.European journal of haematology · 2026Pooled it
- Evaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials.American journal of hematology · 2025Pooled it
- The efficacy of new drug regimens in treating newly diagnosed high-risk cytogenetic multiple myeloma patients: a systematic literature review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Lipid levels and multiple myeloma risk: insights from Meta-analysis and mendelian randomization.Lipids in health and disease · 2024Pooled it
- Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [European journal of nuclear medicine and molecular imaging · 2026Trial
- Measurable Residual Disease.Methods in molecular biology (Clifton, N.J.) · 2027Article
- When MRD Is Not MRD: A Context-Dependent Interpretation in Clinical Decision-Making.European journal of haematology · 2026Article
- Article
- Development and temporal validation of a machine learning-based model for predicting renal impairment in multiple myeloma: a single-center retrospective cohort study.BMC medical informatics and decision making · 2026Article
- Review
- Sustained MRD Negative for 4 Years Is a Significant Marker of Prognosis in Patients with High-Risk Multiple Myeloma.Cancers · 2026Article
- Outcomes Among MM Patients Receiving Early Intervention for MRD Progression Following Autologous Stem Cell Transplantation.Cancer medicine · 2026Article
- t(11;14) multiple myeloma patient: minimal residual disease after 10 years of follow-up - a case report.Haematologica · 2026Article
- The Evolving Role of Genomic Technologies in Multiple Myeloma: Implications for Diagnosis, Risk Stratification and Resistance.Molecular diagnosis & therapy · 2026Review
- Review
- Review
- Treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with multiple myeloma: longer follow-up of the real-world MMY4032 study.Annals of hematology · 2026Observational
- Measurable residual disease testing in acute myeloid leukemia: current state, foundational models, and tools for future development.Cancer metastasis reviews · 2026Review
- Review
- Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real-Life Italian Multicenter Harmonization Experience.Cancer medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is a hematologic malignancy characterized by clonal proliferation of plasma cells. MM is a heterogeneous disease, featured by various molecular subtypes with different outcomes. With the advent of very efficient therapies including monoclonal antibodies, bispecific T-cell engagers and chimeric antigen receptor T cells (CAR T cells), most MM patients now have a prolonged survival. However, the disease remains incurable, and a subgroup of high-risk patients continue to have early relapse and short survival. Novel and highly sensitive methods have been developed allowing the detection of minimal residual disease (MRD) during or after treatment. Achievement of MRD negativity is a strong and independent prognostic factor in both prospective randomized clinical trials and in the real-world setting. While MRD assessment is now a validated endpoint in clinical trials, its incorporation in clinical practice is not yet established and its potential impact on guiding therapy remains under in-depth evaluation. Here we discuss the different methods available for MRD assessment and the role of MRD evaluation in MM management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.